Boehringer Ingelheim's Aptivus can now be used to treat HIV-infected pediatric patients.
Pediatric patients between two and 18 years of age who are infected with HIV have a new treatment available to them. It’s Boehringer Ingelheim Pharmaceuticals’
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.